Johnson & Johnson (JNJ)
Overview
Johnson & Johnson, together with its subsidiaries, researches and develops, manufactures, and sells various products in the healthcare field worldwide. The company's Consumer Health segment offers baby care products under the JOHNSON'S and AVEENO Baby brands; oral care products under the LISTERINE brand; skin health/beauty products under the AVEENO, CLEAN & CLEAR, DR. CI:LABO, NEUTROGENA, and OGX brands; TYLENOL acetaminophen products; SUDAFED cold, flu, and allergy products; BENADRYL and ZYRTEC allergy products; MOTRIN IB ibuprofen products; NICORETTE smoking cessation products; and PEPCID acid reflux products. It also offers STAYFREE and CAREFREE sanitary pads; o.b. tampons; adhesive bandages under the BAND-AID brand; and first aid products under the NEOSPORIN brand. It serves general public, retail outlets, and distributors. The company's Pharmaceutical segment offers products for rheumatoid arthritis, psoriatic arthritis, inflammatory bowel disease, and psoriasis; HIV/AIDS and COVID-19 infectious diseases; mood disorders, neurodegenerative disorders, and schizophrenia; prostate cancer, hematologic malignancies, lung cancer, and bladder cancer; thrombosis, diabetes and macular degeneration; and pulmonary arterial hypertension. This segment serves retailers, wholesalers, distributors, hospitals, and healthcare professionals directly for prescription use. Its MedTech segment provides electrophysiology products to treat cardiovascular diseases; neurovascular care products to treat hemorrhagic and ischemic stroke; orthopaedics products in support of hips, knees, trauma, spine, sports, and other; advanced and general surgery solutions that focus on breast aesthetics, ear, nose, and throat procedures; and disposable contact lenses and ophthalmic products related to cataract and laser refractive surgery under the ACUVUE brand. This segment serves wholesalers, hospitals, and retailers. The company was founded in 1886 and is based in New Brunswick, New Jersey.
Explore More Data
Key Information
Stock Snapshot (Updated: Nov 05 04:00 PM EST)
Capital Structure (Updated: Nov 05 04:00 PM EST)
Calendar Events (Upcoming Earnings & Revenue Forecasts)
| Earnings | |
| Earnings Date | 2026-01-21 |
| Earnings Call | 2025-10-14 |
| Avg EPS Estimate | 2.5354 |
| Low EPS Estimate | 2.48 |
| High EPS Estimate | 2.5844 |
| Revenue | |
| Avg Revenue Forecast | 24,145,424,530 |
| Low Revenue Forecast | 24,043,000,000 |
| High Revenue Forecast | 24,476,473,750 |
JNJ Liquidity Indicators Shows key metrics that reflect cash availability and short-term payment ability
| Field | Value | Description |
|---|---|---|
| Cash Holdings | $18,562,000,896 | Cash on hand, which directly shows a company's ability to meet short-term obligations. |
| Quick Ratio | 0.711 | The quick ratio, which excludes inventory, measures short-term solvency; a value above 1 is considered relatively safe. |
| Current Ratio | 1.074 | The current ratio, calculated as current assets divided by current liabilities; the higher the value, the better the liquidity. |
| Total Debt | $45,795,000,320 | Total liabilities, used together with cash and liquidity ratios to assess debt burden. |
JNJ Profitability Indicators Shows key metrics that reflect overall earnings, margins, and core business profitability
| Field | Value | Description |
|---|---|---|
| EBITDA | $31,921,999,872 | EBITDA (Earnings Before Interest, Taxes, Depreciation, and Amortization), which measures the profitability of core operations. |
| Operating Cash Flow | $24,203,999,232 | Operating cash flow, which reflects a company's cash-generating ability. |
| Free Cash Flow | $12,008,999,936 | Free cash flow, after deducting capital expenditures, which can be used for dividends or reinvestment. |
| Gross Margin | 68.36% | Gross margin; a higher value indicates stronger product profitability. |
| Operating Margin | 30.20% | Operating margin; slightly negative, indicating high operating costs. |
| Profit Margin | 27.26% | Net profit margin, which reflects overall profitability. |
JNJ Leverage & Financial Health Indicators Shows key metrics that reflect debt levels, liquidity, and overall financial stability
| Field | Value | Description |
|---|---|---|
| Debt/Equity Ratio | 57.77% | Low leverage level, indicating the company has low debt pressure. |
| Total Debt | $45,795,000,320 | Used together with cash and EBITDA to assess debt-paying ability. |
JNJ Growth Indicators Shows key financial metrics that reflect profitability, cash flow, and business expansion
| Field | Value | Description |
|---|---|---|
| Revenue Growth (YoY) | 6.80% | Rapid revenue growth, indicating fast business expansion. |
| Earnings Growth (YoY) | 91.00% | Significant EPS growth, indicating rapid improvement in profitability. |
Financial Data for JNJ (Key ratios, margins, and cash flow)
| Field | Value | Description |
|---|---|---|
| Current Price | $186 | Latest stock trading price |
| Price Target (High) | $225 | Analyst highest expected price |
| Price Target (Low) | $155 | Analyst lowest expected price |
| Price Target (Average) | $199.56 | Average target price across analysts |
| Price Target (Median) | $204 | Median of target prices |
| Average Rating Score | 2.17 | Average analyst rating (1=Strong Buy, 5=Sell) |
| Consensus Recommendation | buy | Consensus rating |
| Analyst Coverage Count | 23 | Number of analysts providing estimates |
| Cash Holdings | $18,562,000,896 | Total cash held by the company |
| Cash per Share | $7.70 | Cash value per outstanding share |
| Total Debt | $45,795,000,320 | Company's total debt |
| Quick Ratio | 0.711 | Ability to cover short-term liabilities (excludes inventory) |
| Current Ratio | 1.074 | Overall short-term liquidity |
| Debt/Equity Ratio | 57.77% | Leverage ratio: Debt / Equity |
| EBITDA | $31,921,999,872 | Earnings before interest, taxes, depreciation & amortization |
| Total Revenue | $92,148,998,144 | Total company revenue |
| Revenue per Share | $38.28 | Total revenue divided by shares outstanding |
| Gross Profit | 68.36% | Revenue minus cost of goods sold |
| Return on Assets | 8.26% | Net income / Total assets |
| Return on Equity | 33.62% | Net income / Shareholder equity |
| Earnings Growth (YoY) | 91.00% | Year-over-year EPS growth |
| Revenue Growth (YoY) | 6.80% | Year-over-year revenue growth |
| Gross Margin | 68.36% | Gross profit / Total revenue |
| EBITDA Margin | 34.64% | EBITDA / Revenue |
| Operating Margin | 30.20% | Operating income / Revenue |
| Profit Margin | 27.26% | Net income / Revenue |
| Free Cash Flow | $12,008,999,936 | Cash left after capital expenditures |
| Operating Cash Flow | $24,203,999,232 | Cash from core business operations |
| Currency | USD | Reported in US dollars |
| Last Updated | 2025-11-05 | Data source from Yahoo |